BiotechTube
Oblenio Bio

Oblenio Bio

Cambridge, United States· Est.
obleniobio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Oblenio Bio is a private, pre-clinical stage biotech focused on developing a first-in-class, tri-specific T-cell engager antibody, LBL-051, which dually targets CD19 and BCMA for the treatment of autoimmune diseases. Formed as an Aditum Bio company in November 2024 following an exclusive option to license LBL-051 from Leads Biolabs, the company aims to deplete pathological B-cell lineages to achieve a robust and durable immune reset. Oblenio Bio is positioned to tackle difficult treatment challenges across a broad spectrum of autoimmune conditions with this potentially paradigm-shifting therapeutic approach.

Autoimmune Diseases

Technology Platform

Tri-specific T-cell engager (TCE) antibodies designed to redirect patient T cells to deplete target B-cell populations. The lead platform features dual targeting of CD19 and BCMA on B cells.

Opportunities

The vast, underserved market for severe autoimmune diseases presents a major opportunity for a therapy that can induce deep, durable remission.
Validation of CD19-targeting therapies in autoimmunity de-risks the approach, while Oblenio's dual-targeting strategy could offer superior efficacy and a more convenient off-the-shelf profile compared to cell therapies.

Risk Factors

High clinical risk as the safety and efficacy of a CD19/BCMA dual-targeting T-cell engager in autoimmunity is unproven, with potential for severe cytokine-related toxicities.
The company faces intense competition from other B-cell targeting modalities and is a single-asset entity, making it highly vulnerable to clinical or developmental setbacks.

Competitive Landscape

Oblenio competes in the rapidly evolving field of B-cell depletion and immune reset therapies. Direct competitors include developers of CD19-directed CAR-T (e.g., Kyverna, Cabaletta) and CD19-targeting bispecific antibodies in autoimmunity, as well as established anti-CD20 biologics. Its key differentiator is the dual CD19/BCMA targeting strategy aimed at broader B-lineage depletion.

More companies in Biologics / Biosimilars →More companies in United States →